Takeda’s modality operandi
How Takeda is using external innovation to access new modalities
Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a wide range of collaborations that leverage the company’s expertise while also tapping its partners’ skill sets.
BioCentury sat down with Takeda Chief Medical and Scientific Officer Andrew Plump at BIO’s annual meeting in San Diego to discuss his vision for growing Takeda’s pipeline.
Since Plump joined Takeda in 2015, he has helped to reorganize the company to capitalize on its deep roots in small molecules while also looking externally to bring in new modalities that complement the pharma’s core areas of cancer, CNS and gastrointestinal disorders.
Plump envisions that about 75% of its pipeline growth will come from collaborations, with the expectation that this shift could take three to five years to materialize. The pharma is looking for partners with expertise in niche therapeutic areas that fit its focus areas and in new modalities such as T cell therapies and bispecific antibodies.
Takeda has used a variety of deal structures to leverage and learn from its partners. One example saw the pharma put one of its own programs into the hands of Ovid Therapeutics Inc., a biotech with experience in rare CNS disorders.
Other examples include build-to-buy deals typified by a May pact with newco GammaDelta Therapeutics Ltd. Takeda hopes to learn about a new treatment modality -- gamma delta T cells -- that